Over the last decade, there has been tremendous progress in the treatment of patients with gynecologic cancers with a changing therapy landscape. This summary provides an overview of U.S. Food and Drug Administration (FDA) approvals for gynecologic cancers from 2010-2020, totaling 17 new indications. Current FDA thinking on drug development opportunities and regulatory initiatives currently underway is discussed.
U.S. FDA Drug Approvals for Gynecological Malignancies - A Decade in Review
HPV in Oropharyngeal and Cervical Cancers
Click here to read about cervical cancer and HPV-associated oropharyngeal cancer (OPC). Despite the common etiologic role of HPV in the development of cervical cancer and HPV-associated OPC, great disparity exists between incidence, screening modalities (or lack thereof), treatment, and prevention in these 2 very distinct cohorts. These differences in cervical cancer and HPV-associated OPC and their impact are discussed here.
FDA Approval Summary for ovarian cancer maintenance regimen
Here is the FDA approval summary for olaparib as monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer.